
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+8
Mesentech is a clinical stage biotechnology company developing novel medicines that selectively distribute to the intended site of action. MES1022 is a clinical stage program for bone-repair being developed for 3 indications. Our preclinical pipeline includes novel compounds targeting bone-cancers
Osteoporosis,osteogenesis imperfecta,brittle bone disease,orphan disease,implants,fracture healing,regenerative medicine,bone-graft,biomaterials,bone,bone-loss,drug conjugate,and duchenne
Mesentech operates in the Biotechnology industry.
Mesentech's revenue is 11m - 100m
Mesentech has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.